Ixtapaluca

Researchers are investigating a new treatment approach for children aged 6 months to less than 18 years who have chronic kidney disease (CKD) and proteinuria, a condition where the kidneys leak protein into the urine. CKD causes the kidneys to work less effectively, leading to waste buildup and high blood pressure. Current treatments include ACE inhibitors (ACEI) or angiotensin receptor blockers (ARB), which help regulate a system involved in blood pressure and kidney function. However, these treatments do not work for all patients. This study is focused on seeing if adding finerenone to ACEI or ARB can better control this system and improve kidney function. Participants will receive either finerenone or a placebo for about 180 days, alongside their usual ACEI or ARB medication. The study will adjust finerenone doses based on age and body weight. Before starting treatment, participants will attend up to two screening visits within 104 days to check eligibility. During the treatment phase, participants will make at least seven visits to the study site for ongoing care and monitoring. Throughout the study, doctors will measure participants' blood pressure, heart rate, temperature, height, and weight. They will collect blood and urine samples to monitor kidney function and protein levels. Heart health will be checked using electrocardiograms and echocardiography. Participants or their parents will answer questions about medication use, side effects, and how they feel. Researchers will track any medical problems that occur during the study and will follow up about 30 days after treatment ends. The main goal is to see how much the protein in urine changes from the start to day 180.

Researchers are studying the effects of cancer diagnosis and treatment during pregnancy on both mothers and their children. The aim is to understand the overall survival of mothers diagnosed with cancer during pregnancy and to test whether children exposed to cancer treatments like chemotherapy or radiation in the womb develop normally, particularly focusing on neurological and heart health. The study includes several parts addressing maternal health during and after pregnancy and long-term follow-up of children exposed to cancer treatments before birth. The study involves registering mothers diagnosed with cancer during pregnancy and collecting maternal blood samples, umbilical cord blood, and tissue samples from the placenta and umbilical cord. Mothers complete questionnaires about anxiety and emotional needs related to their diagnosis. Children who were exposed to cancer treatments in the womb will have regular health check-ups at ages 6 months, 18 months, 3, 6, 9, 12, 15, and 18 years. After age 18, cardiologic assessments and questionnaires will continue every five years, with optional MRI scans at several ages during childhood and adolescence. Participants will be monitored through neurological and cardiological exams performed by specialists to assess the children's development. Mothers’ outcomes will be tracked prospectively from diagnosis through treatment and delivery. The study includes long-term follow-up for both mothers and children, with comprehensive assessments to evaluate health effects over many years. Participants provide informed consent, and children older than 12 provide assent with consent from parents or themselves once they reach adulthood.